July 19, 2012 - AML - Emerging Treatment Strategies
Your order contains item(s) View Order
- Signs or symptoms of acute myeloid leukemia (AML)
- Blood and marrow tests used to diagnose AML
- Current and emerging treatment options
- Treatment side effects and strategies for side effect management
- The role of clinical trials in the continuing improvement of AML treatment outcomes
- Information and support resources for patients and caregivers
Wendy Stock, MD
Professor of Medicine, Section of Hematology/Oncology
Director, Leukemia Program
The University of Chicago Medicine
Questions Asked by the AML Community
- Is there a role for molecular diagnosis as a guide to maintenance therapy, to keep a patient in remission?
- Would you be able to comment at all on your recommendations for second transplant for high-risk groups such as FLT3 who relapsed after a first allogeneic bone marrow transplant?
- Would a 74-year-old woman in otherwise good health ever be a candidate for a stem cell transplant?
- What kind of research is being done and what is the success rate of using stem cells from umbilical cords?
- Does it take longer for a person to recover from a double cord transplant?
- Do you have any information about the Celator Trial, CPX-351? If so, could you discuss that?
- After an original diagnosis of AML and successful treatment, the diagnosis has been modified to MDS evolved into AML. What gets treated now, the AML or the MDS?
- After 16 months in remission, what is the risk of the disease becoming active again?
Sponsors and Supporters
This program was sponsored by The Leukemia & Lymphoma Society.